3 results match your criteria 67-76 ebov

  • Page 1 of 1

Crystal structure of human LC8 bound to a peptide from Ebola virus VP35.

J Microbiol 2021 Apr 25;59(4):410-416. Epub 2021 Feb 25.

Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.

Zaire ebolavirus, commonly called Ebola virus (EBOV), is an RNA virus that causes severe hemorrhagic fever with high mortality. Viral protein 35 (VP35) is a virulence factor encoded in the EBOV genome. VP35 inhibits host innate immune responses and functions as a critical cofactor for viral RNA replication. Read More

View Article and Full-Text PDF

Treatment-focused Ebola trials, supportive care and future of filovirus care.

Expert Rev Anti Infect Ther 2018 01 20;16(1):67-76. Epub 2017 Dec 20.

b Division of Medicine , United States Army Medical Research Institute of Infectious Diseases , Frederick , MD , USA.

Introduction: During the 2014-2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Read More

View Article and Full-Text PDF
January 2018

Development of treatment strategies to combat Ebola and Marburg viruses.

Expert Rev Anti Infect Ther 2006 Feb;4(1):67-76

Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702-5011, USA.

Ebola and Marburg viruses are emerging/re-emerging pathogens that pose a significant threat to human health. These naturally occurring viral infections frequently cause a lethal hemorrhagic fever in humans and nonhuman primates. The disastrous consequences of infection with these viruses have been pursued as potential biological weapons. Read More

View Article and Full-Text PDF
February 2006
  • Page 1 of 1